Search 

Atopix Therapeutics Limited is a clinical stage biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma.

The company is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists.

• Our lead candidate, OC459, is currently being studied in a Phase 2 clinical trial for moderate to severe atopic dermatitis in Europe and in a Phase 3 clinical trial for moderate persistent eosinophilic asthma in Russia.
• Our back-up, ATX2417, is undergoing a Phase 1 human safety study.

Later in the year, we plan to start a Phase 2 proof-of-concept study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids.

Crescendo Biologics is focused on the discovery and development of best-in-class Humabody™ VH fragment therapeutics, using its novel transgenic platform. Crescendo is enabling the major VH product formats (multivalent, half-life-extended and topical) for its own pipeline, focused in oncology (immuno-oncology, checkpoint inhibitor and ADC, Humabody Drug Conjugate programmes) and inflammation, and to make it the partner of choice for human VH fragment therapeutics.